|
|
| (20 intermediate revisions by 2 users not shown) |
| redirect | redirect |
| | | Q3698691 |
| label / fr | label / fr |
| 12012 - MIMEDI
|
| label / en | label / en |
| 12012 — MIMEDI
|
| description / en | description / en |
| Project in France financed by DG Regio
|
| description / fr | description / fr |
| Projet en France financé par DG Regio
|
| Property / French Kohesio ID | |
| 10341
| |
| Property / French Kohesio ID: 10341 / rank | |
| Normal rank
| |
| Property / instance of | |
| | |
| Property / instance of: Kohesio project / rank | |
| Normal rank
| |
| Property / country | |
| | |
| Property / country: France / rank | |
| Normal rank
| |
| Property / EU contribution | |
| 10,211,026.83 Euro| Amount | 10,211,026.83 Euro |
|---|
| Unit | Euro |
|---|
| |
| Property / EU contribution: 10,211,026.83 Euro / rank | |
| Normal rank
| |
| Property / budget | |
| 13,614,711.32 Euro| Amount | 13,614,711.32 Euro |
|---|
| Unit | Euro |
|---|
| |
| Property / budget: 13,614,711.32 Euro / rank | |
| Normal rank
| |
| Property / postal code | |
| 25030
| |
| Property / postal code: 25030 / rank | |
| Normal rank
| |
| Property / start time | |
| 1 December 2017| Timestamp | +2017-12-01T00:00:00Z |
|---|
| Timezone | +00:00 |
|---|
| Calendar | Gregorian |
|---|
| Precision | 1 day |
|---|
| Before | 0 |
|---|
| After | 0 |
|---|
| |
| Property / start time: 1 December 2017 / rank | |
| Normal rank
| |
| Property / end time | |
| 30 November 2021| Timestamp | +2021-11-30T00:00:00Z |
|---|
| Timezone | +00:00 |
|---|
| Calendar | Gregorian |
|---|
| Precision | 1 day |
|---|
| Before | 0 |
|---|
| After | 0 |
|---|
| |
| Property / end time: 30 November 2021 / rank | |
| Normal rank
| |
| Property / beneficiary name (string) | |
| Université de Franche-Comté
| |
| Property / beneficiary name (string): Université de Franche-Comté / rank | |
| Normal rank
| |
| Property / summary | |
| Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
| |
| Property / summary: Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French) / rank | |
| Normal rank
| |
| Property / summary | |
| Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get involved, Migradi brings together research and industrial research laboratories from both the engineering and the cellular engineering sciences. (English)
| |
| Property / summary: Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get involved, Migradi brings together research and industrial research laboratories from both the engineering and the cellular engineering sciences. (English) / rank | |
| Normal rank
| |
| Property / intervention field | |
| | |
| Property / intervention field: Technology transfer and university-enterprise cooperation primarily benefiting SMEs / rank | |
| Normal rank
| |
| Property / coordinate location | |
| 47°14'23.03"N, 6°0'44.14"E| Latitude | 47.239733666667 |
|---|
| Longitude | 6.0122559333333 |
|---|
| Precision | 1.0E-5 |
|---|
| Globe | http://www.wikidata.org/entity/Q2 |
|---|
| |
| Property / coordinate location: 47°14'23.03"N, 6°0'44.14"E / rank | |
| Normal rank
| |
| Property / financed by | |
| | |
| Property / financed by: European Union / rank | |
| Normal rank
| |
| Property / financed by | |
| | |
| Property / financed by: Directorate-General for Regional and Urban Policy / rank | |
| Normal rank
| |
| Property / programme | |
| | |
| Property / programme: Franche-Comté et Jura - ERDF/ESF / rank | |
| Normal rank
| |
| Property / co-financing rate | |
| | |
| Property / co-financing rate: 75.0 percent / rank | |
| Normal rank
| |